Alchemab bags fresh round of in­vestors for tar­get-ag­nos­tic an­ti­body de­vel­op­ment for Hunt­ing­ton's, Covid-19

With a “tar­get-ag­nos­tic” ap­proach to an­ti­body de­vel­op­ment, the UK’s Alchemab has used lessons learned from pa­tients with re­sis­tance to cer­tain dis­eases to chase af­ter con­di­tions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER